EGCG for the Prevention and Treatment of TIPN — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

EGCG for the Prevention and Treatment of TIPN — Stella

Recruiting

Back to Chemotherapy-induced Peripheral Neuropathy trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

Shandong First Medical University Affiliated Cancer Hospital (Shandong Academy of Medical Sciences), Jinan, Shandong

Key details

Phase

Early testing / Safety & dosing

Sponsor

Han Xi Zhao

Collaborators

The Fourth People's Hospital of Jinan

Enrollment target

~36 participants

Started

November 2023

Primary completion

November 2024

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years and older

Last updated July 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov